Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A

Molecular Pharmacology

Volumn 86, Issue 4, 2014, Pages 438-449

  Hanna, Amy D ^a,b   Lam, Alex ^a   Tham, Steffi ^a   Dulhunty, Angela F ^a   Beard, Nicole A ^a,c  

^a Biology and Environment   (Australia)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CANBERRA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DITHIOTHREITOL; DOXORUBICIN; DOXORUBICINOL; RYANODINE RECEPTOR 2; SARCOPLASMIC ENDOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; THIOL GROUP; UNCLASSIFIED DRUG; CALCIUM; CARDIOTOXIN; DRUG DERIVATIVE; RYANODINE RECEPTOR;

ARTICLE; CALCIUM SIGNALING; CALCIUM TRANSPORT; CARDIOTOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HEART MUSCLE CELL; NONHUMAN; OXIDATION; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN MODIFICATION; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; ANIMAL; LIPID BILAYER; METABOLISM; PROTEIN BINDING; SARCOPLASMIC RETICULUM; SHEEP;

ANIMALS; CALCIUM; CALCIUM SIGNALING; CARDIOTOXINS; DOXORUBICIN; LIPID BILAYERS; PROTEIN BINDING; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SHEEP;

EID: 84907918245     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.093849     Document Type: Article

References (66)

1. Abramson JJ, Buck E, Salama G, Casida JE, and Pessah IN (1988) Mechanism of anthraquinone-induced calcium release from skeletal muscle sarcoplasmic reticulum. J Biol Chem 263:18750-18758.
2. Adachi T, Weisbrod RM, Pimentel DR, Ying J, Sharov VS, Schöneich C, and Cohen RA (2004) S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med 10:1200-1207.
3. Aghdasi B, Zhang JZ, Wu Y, Reid MB, and Hamilton SL (1997) Multiple classes of sulfhydryls modulate the skeletal muscle Ca2+ release channel. J Biol Chem 272: 3739-3748.
4. Arai M, Tomaru K, Takizawa T, Sekiguchi K, Yokoyama T, Suzuki T, and Nagai R (1998) Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J Mol Cell Cardiol 30:243-254.
5. Beard NA, Sakowska MM, Dulhunty AF, and Laver DR (2002) Calsequestrin is an inhibitor of skeletal muscle ryanodine receptor calcium release channels. Biophys J 82:310-320.
6. Beard NA, Wei L, Cheung SN, Kimura T, Varsanyi M, and Dulhunty, AF. (2008) Phosphorylation of skeletal muscle calsequestrin enhances its Ca2+ binding capacity and promotes its association with junctin. Cell Calcium 44:363-373.
7. Belevych AE, Terentyev D, Viatchenko-Karpinski S, Terentyeva R, Sridhar A, Nishijima Y, Wilson LD, Cardounel AJ, Laurita KR, and Carnes CA et al. (2009) Redox modification of ryanodine receptors underlies calcium alternans in a canine model of sudden cardiac death. Cardiovasc Res 84:387-395.
8. Bers DM (2002) Calcium and cardiac rhythms: physiological and pathophysiological. Circ Res 90:14-17.
9. Bers DM, Eisner DA, and Valdivia HH (2003) Sarcoplasmic reticulum Ca2+ and heart failure: roles of diastolic leak and Ca2+ transport. Circ Res 93:487-490.
10. Boucek Jr RJ, Dodd DA, Atkinson JB, Oquist N, and Olson RD (1997) Contractile failure in chronic doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol 29: 2631-2640.
11. Boucek Jr RJ, Miracle A, Anderson M, Engelman R, Atkinson J, and Dodd DA (1999) Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol 31: 1435-1446.
12. Burgoyne JR, Mongue-Din H, Eaton P, and Shah AM (2012) Redox signaling in cardiac physiology and pathology. Circ Res 111:1091-1106.
13. Butler J and Hoey BM (1993) The one-electron reduction potential of several substrates can be related to their reduction rates by cytochrome P-450 reductase. Biochim Biophys Acta 1161:73-78.
14. Charlier Jr HA, Olson RD, Thornock CM, Mercer WK, Olson DR, Broyles TS, Muhlestein DJ, Larson CL, Cusack BJ, and Shadle SE (2005) Investigations of calsequestrin as a target for anthracyclines: comparison of functional effects of daunorubicin, daunorubicinol, and trifluoperazine. Mol Pharmacol 67:1505-1512.
15. Cusack BJ, Mushlin PS, Voulelis LD, Li X, Boucek Jr RJ, and Olson RD (1993) Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol? Toxicol Appl Pharmacol 118:177-185.
16. Cusack BJ, Young SP, and Olson RD (1995) Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat. Cancer Chemother Pharmacol 35:213-218.
17. Donoso P, Sanchez G, Bull R, and Hidalgo C (2011) Modulation of cardiac ryanodine receptor activity by ROS and RNS. Front Biosci (Landmark Ed) 16: 553-567.
18. Dulhunty AF, Laver DR, Gallant EM, Casarotto MG, Pace SM, and Curtis S (1999) Activation and inhibition of skeletal RyR channels by a part of the skeletal DHPR II-III loop: effects of DHPR Ser687 and FKBP12. Biophys J 77:189-203.
19. Dulhunty AF, Pouliquin P, Coggan M, Gage PW, and Board PG (2005) A recently identified member of the glutathione transferase structural family modifies cardiac RyR2 substate activity, coupled gating and activation by Ca2+ and ATP. Biochem J 390:333-343.
20. Eager KR, Roden LD, and Dulhunty AF (1997) Actions of sulfhydryl reagents on single ryanodine receptor Ca(2+)-release channels from sheep myocardium. Am J Physiol 272:C1908-C1918.
21. Eager KR and Dulhunty AF (1999) Cardiac ryanodine receptor activity is altered by oxidizing reagents in either the luminal or cytoplasmic solution. J Membr Biol 167: 205-214.
22. Feng W, Liu G, Xia R, Abramson JJ, and Pessah IN (1999) Site-selective modification of hyperreactive cysteines of ryanodine receptor complex by quinones. Mol Pharmacol 55:821-831.
23. Forrest GL, Gonzalez B, Tseng W, Li X, and Mann J (2000) Human carbonyl reductase overexpression in the heart advances the development of doxorubicininduced cardiotoxicity in transgenic mice. Cancer Res 60:5158-5164.
24. Gambetta RA, Colombo A, Lanzi C, and Zunino F (1983) Purification and partial characterization of a daunorubicin-binding protein from rat liver. Mol Pharmacol 24:336-340.
25. Gambliel HA, Burke BE, Cusack BJ, Walsh GM, Zhang YL, Mushlin PS, and Olson RD (2002) Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. Biochem Biophys Res Commun 291:433-438.
26. Gant TW, Rao DN, Mason RP, and Cohen GM (1988) Redox cycling and sulphydryl arylation; their relative importance in the mechanism of quinone cytotoxicity to isolated hepatocytes. Chem Biol Interact 65:157-173.
27. Gilliam LA and St Clair DK (2011) Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid Redox Signal 15:2543-2563.
28. Goodman J and Hochstein P (1977) Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochem Biophys Res Commun 77: 797-803.
29. Hanna AD, Janczura M, Cho E, Dulhunty AF, and Beard NA (2011) Multiple actions of the anthracycline daunorubicin on cardiac ryanodine receptors. Mol Pharmacol 80:538-549.
30. Jalilian C, Gallant EM, Board PG, and Dulhunty AF (2008) Redox potential and the response of cardiac ryanodine receptors to CLIC-2, a member of the glutathione S-transferase structural family. Antioxid Redox Signal 10:1675-1686.
31. Jayaraman T, Brillantes AM, Timerman AP, Fleischer S, Erdjument-Bromage H, Tempst P, and Marks AR (1992) FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem 267:9474-9477.
32. Kang C, Nissen MS, Sanchez EJ, Lam KS, and Milting H (2010) Potential adverse interaction of human cardiac calsequestrin. Eur J Pharmacol 646:12-21.
33. Karim CB, Paterlini MG, Reddy LG, Hunter GW, Barany G, and Thomas DD (2001) Role of cysteine residues in structural stability and function of a transmembrane helix bundle. J Biol Chem 276:38814-38819.
34. Kushnir A and Marks AR (2010) The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol 59:1-30.
35. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
36. Laver DR, Roden LD, Ahern GP, Eager KR, Junankar PR, and Dulhunty AF (1995) Cytoplasmic Ca2+ inhibits the ryanodine receptor from cardiac muscle. J Membr Biol 147:7-22.
37. Marchini S, Gonzalez Paz O, Ripamonti M, Geroni C, Bargiotti A, Caruso M, Todeschi S, D'Incalci M, and Broggini M (1995) Sequence-specific DNA interactions by novel alkylating anthracycline derivatives. Anticancer Drug Des 10: 641-653.
38. Marinov BS, Olojo RO, Xia R, and Abramson JJ (2007) Non-thiol reagents regulate ryanodine receptor function by redox interactions that modify reactive thiols. Antioxid Redox Signal 9:609-621.
39. Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, and Minotti G (2012) Anthracycline cardiotoxicity. Expert Opin Drug Saf 11 (Suppl 1):S21-S36.
40. Mushlin PS, Cusack BJ, Boucek Jr RJ, Andrejuk T, Li X, and Olson RD (1993) Timerelated increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 110: 975-982.
41. Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, and Reeves RH (2003) Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 63:6602-6606.
42. Olson RD, Mushlin PS, Brenner DE, Fleischer S, Cusack BJ, Chang BK, and Boucek Jr RJ (1988) Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85:3585-3589.
43. Olson RD, Li X, Palade P, Shadle SE, Mushlin PS, Gambliel HA, Fill M, Boucek Jr RJ, and Cusack BJ (2000) Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicol Appl Pharmacol 169: 168-176.
44. Ondrias K, Borgatta L, Kim DH, and Ehrlich BE (1990) Biphasic effects of doxorubicin on the calcium release channel from sarcoplasmic reticulum of cardiac muscle. Circ Res 67:1167-1174.
45. Paavola J, Viitasalo M, Laitinen-Forsblom PJ, Pasternack M, Swan H, Tikkanen I, Toivonen L, Kontula K, and Laine M (2007) Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves. Eur Heart J 28: 1135-1142.
46. Park IY, Kim EJ, Park H, Fields K, Dunker AK, and Kang C (2005) Interaction between cardiac calsequestrin and drugs with known cardiotoxicity. Mol Pharmacol 67:97-104.
47. Pessah IN, Durie EL, Schiedt MJ, and Zimanyi I (1990) Anthraquinone-sensitized Ca2+ release channel from rat cardiac sarcoplasmic reticulum: possible receptormediated mechanism of doxorubicin cardiomyopathy. Mol Pharmacol 37:503-514.
48. Sacco G, Giampietro R, Salvatorelli E, Menna P, Bertani N, Graiani G, Animati F, Goso C, Maggi CA, and Manzini S et al. (2003) Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. Br J Pharmacol 139:641-651.
49. Sag CM, Köhler AC, Anderson ME, Backs J, and Maier LS (2011) CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. J Mol Cell Cardiol 51:749-759.
50. Shadle SE, Bammel BP, Cusack BJ, Knighton RA, Olson SJ, Mushlin PS, and Olson RD (2000) Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Biochem Pharmacol 60:1435-1444.
51. Simunek T, Stérba M, Popelová O, Adamcová M, Hrdina R, and Gersl V (2009) Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61:154-171.
52. Tong GL,Wu HY, Smith TH, and HenryDW (1979) Adriamycin analogues. 3. Synthesis of N-alkylated anthracyclines with enhanced efficacy and reduced cardiotoxicity. J Med Chem 22:912-918.
53. Towbin H, Staehelin T, and Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354.
54. Trachtenberg BH, Landy DC, Franco VI, Henkel JM, Pearson EJ, Miller TL, and Lipshultz SE (2011) Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol 32:342-353.
55. van Dalen EC, van der Pal HJ, Caron HN, and Kremer LC (2009) Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev (4):CD005008.
56. van Norren K, van Helvoort A, Argilés JM, van Tuijl S, Arts K, Gorselink M, Laviano A, Kegler D, Haagsman HP, and van der Beek EM (2009) Direct effects of doxorubicin on skeletal muscle contribute to fatigue. Br J Cancer 100:311-314.
57. Voss AA, Lango J, Ernst-Russell M, Morin D, and Pessah IN (2004) Identification of hyperreactive cysteines within ryanodine receptor type 1 by mass spectrometry. J Biol Chem 279:34514-34520.
58. Wall SB, Oh JY, Diers AR, and Landar A (2012) Oxidative modification of proteins: an emerging mechanism of cell signaling. Front Physiol 3:369.
59. Wang GX, Wang YX, Zhou XB, and Korth M (2001) Effects of doxorubicinol on excitation-contraction coupling in guinea pig ventricular myocytes. Eur J Pharmacol 423:99-107.
60. Wang X, Thomas B, Sachdeva R, Arterburn L, Frye L, Hatcher PG, Cornwell DG, and Ma J (2006) Mechanism of arylating quinone toxicity involving Michael adduct formation and induction of endoplasmic reticulum stress. Proc Natl Acad Sci USA 103:3604-3609.
61. Winterbourn CC, Gutteridge JM, and Halliwell B (1985) Doxorubicin-dependent lipid peroxidation at low partial pressures of O2. J Free Radic Biol Med 1:43-49.
62. Xu L, Eu JP, Meissner G, and Stamler JS (1998) Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 279:234-237.
63. Yano M, Yamamoto T, Ikemoto N, and Matsuzaki M (2005) Abnormal ryanodine receptor function in heart failure. Pharmacol Ther 107:377-391.
64. Zable AC, Favero TG, and Abramson JJ (1997) Glutathione modulates ryanodine receptor from skeletal muscle sarcoplasmic reticulum. Evidence for redox regulation of the Ca2+ release mechanism. J Biol Chem 272:7069-7077.
65. Zima AV and Blatter LA (2006) Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 71:310-321.
66. Zorzato F, Salviati G, Facchinetti T, and Volpe P (1985) Doxorubicin induces calcium release from terminal cisternae of skeletal muscle. A study on isolated sarcoplasmic reticulum and chemically skinned fibers. J Biol Chem 260:7349-7355.